14th International Conference on Gynecology

To assess whether vaccination against coronavirus disease 2019 is associated with changes in cycle or menstrual length in vaccinated individuals compared to unvaccinated cohorts. We used the Natural Cycles application to analyze the positively recorded menstrual cycle data. US citizens aged 18-45 years, 3 consecutive cycles before the first vaccination (cycles 4-6), or a normal cycle length of 6 cycles (24-38 days) if not vaccinated there is. Period Included period. Averages within individual variations in cycle and menstrual length were calculated (3 cycles before vaccination vs. the first and second dosing cycles of the vaccinated cohort, and the first 3 cycles vs. the non-vaccinated cohort. Cycles 4 and 5). A mixed-effects model was used to estimate adjusted differences in cycle and menstrual length changes between vaccinated and non-vaccinated cohorts. We included 3,959 subjects (2,403 vaccinated; 1,556 unvaccinated). The majority of the vaccinated cohorts received the PfizerBioN

Evaluation of immune response to mRNA-based vaccine against coronavirus disease 2019 (COVID19) present in breast milk and transmission of immune response to breast-fed infants We enrolled 30 lactating women who received mRNAbased COVID19 vaccines from January through April 2021 in this cohort study. Women provided serial milk samples, including milk expressed before vaccination, across 2–3 weeks after the first dose, and across 3 weeks after the second dose. Women provided their blood, spotted on cards (dried blood spots), 19 days after the first dose and 21 days after the second dose. Stool samples from the breastfed infants were collected 21 days after mothers second vaccination. Prepandemic samples of milk, dried blood spots, and infant stool were used as controls. Milk, dry blood stains, and baby stools were tested for receptor-binding domain (RBD) -specific immunoglobulin (Ig) A and IgG using enzyme immunoassays. Milk samples were tested for the presence of neutralizing antibodies